April 2012 Drug Information Update - Pharmacy Benefits ...

More documents

Recommendations

Info

Products Affected - Description Droperidol injection, 2.5 mg/mL, American Regent 2 mL vials (NDC 00517-9702-25) Droperidol injection, 2.5 mg/mL, Hospira 2 mL ampule (NDC 00409-1187-01) Reason for the Shortage • American Regent had temporarily suspended distribution of most drug products including droperidol injection in April, 2011. • American Regent resumed manufacturing in Shirley, New York in early-May, 2011. • Hospira has droperidol on shortage due to increased demand for the product. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=818 Source: www.ashp.org Calcium Chloride Injection March 5, 2012 Products Affected - Description Calcium Chloride 100 mg/mL Injection, Hospira 100 mg/mL, 10 mL Ansyr syringe (NDC 00409-1631-10) 100 mg/mL, 10 mL LifeShield syringe (NDC 00409-4928-34) Reason for the Shortage • American Regent had temporarily suspended distribution of most drug products including calcium chloride in April, 2011. • American Regent resumed manufacturing in Shirley, New York in early-May, 2011. • Hospira has calcium chloride on shortage due to manufacturing delays. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=657 Source: www.ashp.org PCA Sterile Empty Vials and Injector March 06, 2012 Products Affected – Description Lifecare PCA sterile empty vials and injector, Hospira 30 mL sterile empty vials with injector, List Number: 06021-03 Reason for the Shortage • Hospira has Lifecare PCA sterile empty vials with injector on shortage due to manufacturing delays. • These vials are only compatible with Lifecare PCA systems. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=886 Source: www.ashp.org Enalaprilat Injection March 6, 2012 Products Affected - Description Enalaprilat Injection, Bedford 1.25 mg/mL, 1 mL vial (NDC 55390-0010-10) 1.25 mg/mL, 2 mL vial (NDC 55390-0011-10) Enalaprilat Injection, Hospira 1.25 mg/mL, 1 mL vial (NDC 00409-2122-01) 1.25 mg/mL, 2 mL vial (NDC 00409-2122-02) 36
Reason for the Shortage • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011 on a temporary basis for maintenance and requalification of equipment. Product will become available in stages as production resumes. • Bedford Laboratories has multiple products affected by this suspension of manufacturing. Availability of all products, including those not manufactured at Ben Venue, is updated as information changes on the Bedford Laboratories website. • Teva has discontinued both of their products. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=587 Source: www.ashp.org Dipyridamole Injection March 6, 2012 Products Affected - Description Dipyridamole 5 mg/mL injection, Teva 2 mL vial (NDC 00703-1652-02) - discontinued 10 mL vial (NDC 00703-1654-02) - discontinued 2 mL vial, 25 count (NDC 00703-1652-04) 10 mL vial, 10 count (NDC 00703-1654-03) Reason for the Shortage • Bedford discontinued dipyridamole injection in May, 2011 to concentrate on the manufacturing of other products. • Teva has temporarily discontinued their 2 mL and 10 mL products in order to increase the package sizes. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=465 Source: www.ashp.org Nystatin Oral Suspension March 7, 2012 Products Affected - Description Nystatin Oral Suspension, 100,000 units/mL, Qualitest 60 mL (NDC 00603-1481-49) 473 mL (NDC 00603-1481-58) Reason for the Shortage • Fougera and Actavis have discontinued nystatin oral suspension. • Qualitest states the reason for the shortage is a raw materials shortage. • Taro and PAI could not provide a reason for the shortage. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=841 Source: www.ashp.org Metaxalone Tablets March 7, 2012 Products Affected - Description Metaxalone tablets, CorePharma 800 mg, 100 count (NDC 64720-0321-10) Reason for the Shortage • CorePharma states the shortage is due to increased demand. • Pfizer could not provide a reason for the shortage. 37
Page 1 and 2: April 2012 Drug Information Update
Page 3 and 4: First-Time Generics GENERIC DRUG NA
Page 5 and 6: GENERAL ANESTHETICS, INJECTABLE MID
Page 7 and 8: Gruenhaupt, Mark R.Ph. Argus Health
Page 9 and 10: Statin Drugs - Drug Safety Communic
Page 11 and 12: Vytorin (ezetimibe/simvastatin) Tab
Page 13 and 14: low blood sugar (hypoglycemia) in p
Page 15 and 16: Some women with depression who beco
Page 17 and 18: Survival increased for all groups o
Page 19 and 20: finding that it also may reduce the
Page 21 and 22: Syringes (2 mL size), Rx only. NDC
Page 23 and 24: Patheon Pharmaceuticals Inc., Cinci
Page 25 and 26: 50-ct. bottles (NDC 0067-6238-50);
Page 27 and 28: PRODUCT (Class II) 1) Ventolin HFA
Page 29 and 30: Lot #: 0693, Exp: 10/2012 RECALLING
Page 31 and 32: 24 (Display case UPC# 3030045074923
Page 33 and 34: CODE Lot # 139961 RECALLING FIRM/MA
Page 35: Reason for the Shortage • Teva co
Page 39 and 40: Products Affected - Description Gan
Page 41 and 42: 37.5 mg/25 mg, 1000 count (NDC 0078
Page 43 and 44: Acyclovir tablets, Major 400 tablet
Page 45 and 46: 500 mg, 100 count (NDC 63304-0726-0
Page 47 and 48: 750 mg tablets, 100 count (NDC 1013
Page 49 and 50: • Bedford Laboratories has multip
Page 51 and 52: Daunorubicin Hydrochloride Injectio
Page 53 and 54: Ciprofloxacin Immediate-Release Tab
Page 55 and 56: • APP had tobramycin 40 mg/mL pre
Page 57 and 58: • Ben Venue voluntarily suspended
Page 59 and 60: 50 mg/mL, 10 mL vial, package of 10
Page 61 and 62: 2 mL vial, preservative-free (NDC 6
Page 63 and 64: 5 mg single dose vial, package of 1
Page 65 and 66: 20 mL glass ampule, sterile pack (N
Page 67 and 68: 2 mL iSecure syringe (NDC 00406-112
Page 69 and 70: Lidocaine 0.5% Xylocaine 0.5% injec
Page 71 and 72: • Teva discontinued all ciproflox
Page 73 and 74: Nicardipine hydrochloride injection
Page 75 and 76: Article link: http://www.ashp.org/D
Page 77 and 78: • Apotex had metformin products u
Page 79: • Covis purchased all rights to F

April 2012 Drug Information Update - Pharmacy Benefits ...

Create successful ePaper yourself

Delete template?

Save as template?